-
Mashup Score: 14Illustrated Glossary - NEJM - 10 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 4Illustrated Glossary - NEJM - 10 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Somatic variant: A genetic change occurring in any cell of the body except sperm and egg cells. https://t.co/OJ94kcBEJ4 Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozq1Z
-
-
Mashup Score: 0Illustrated Glossary - NEJM - 10 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Clonal hematopoiesis: The clonal expansion of a hematopoietic stem cell and its progeny, driven by a somatic genetic variant and leading to its overrepresentation in the blood. https://t.co/Ymx38NyEtU Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozq1Z
-
-
Mashup Score: 6Illustrated Glossary - NEJM - 10 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Hematopoietic stem cell: A type of stem cell that differentiates into the cellular components of the blood, including red cells, granulocytes, lymphocytes, monocytes, and platelets. https://t.co/a1dEsdz8fT Explore more terms: https://t.co/6Ixo6ozXRx https://t.co/SYjnRNjGwr
-
-
Mashup Score: 2Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma - 10 month(s) ago
In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy…
Source: New England Journal of MedicineCategories: Hem/Onc News and Journals, Hem/Oncs, Latest HeadlinesTweet-
CAR-T therapy for large B-cell lymphoma continues to show promise compared to standard chemotherapy in the second-line setting based on the results of the ZUMA-7. We also hope this provides further justification to improve our CAR manufacturing times.
-
-
Mashup Score: 14Illustrated Glossary - NEJM - 10 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Liquid biopsy: Biologic material obtained from biologic fluids, such as blood, plasma, urine, or ascites, can be analyzed for the presence of abnormal cells or biomolecules (e.g., DNA), proteins, and cell organelles (e.g., endosomes). https://t.co/u26br5rXn1 https://t.co/7TV9vYbClO
-
-
Mashup Score: 12Illustrated Glossary - NEJM - 11 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Lesion network map: A brain atlas in which lesions in different locations that cause the same symptoms are mapped. https://t.co/DWYsrEmDkH Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozXRx https://t.co/LYNEw1oBd1
-
-
Mashup Score: 10Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma - 11 month(s) ago
In an analysis of the primary outcome of this phase 3 trial, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T-cell therapy, as second-line treatment had significantly longer event-free survival than those who received standard care.
Source: New England Journal of MedicineCategories: Expert Picks, Latest HeadlinesTweet-
Conclusion: axi-cel should be standard second-line treatment for patients with DLBCL who relapse within the first year. Hopefully this OS benefit leads to regulatory approval in 2L context in many places Full paper out at @NEJM : https://nejm.org/doi/full/10.1056/NEJMoa2301665?query=featured_home #ASCO23 #lymsm
-
-
Mashup Score: 29Illustrated Glossary - NEJM - 11 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Epigenetic change: A change in the regulation of the expression of gene activity without alteration of genetic structure. https://t.co/UtoKQeLxWc Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozXRx https://t.co/XOutM3YM6J
-
-
Mashup Score: 9Illustrated Glossary - NEJM - 11 month(s) ago
Illustrated Glossary from The New England Journal of Medicine
Source: New England Journal of MedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
Somitogenesis: The process by which somites form in a developing embryo, commencing at the end of the third week of gestation. https://t.co/GBpwf55NWm Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozXRx https://t.co/axAw3qfgNA
-
G protein–coupled receptor: A cell‐surface receptor that, once activated by ligand at the cell’s exterior, sets off a cascade of intracellular events. https://t.co/nsFrw4H9aT Explore more terms from the NEJM Illustrated Glossary: https://t.co/6Ixo6ozq1Z